Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.46 |
| ▸ | CDC25B | P30305 | 1/20 | 0.46 |
| ▸ | AKT1 | P31749 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | DRD1 | P21728 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9354843 | 0.87 | LMNA (0.55) | LMNAPTPN1CDC25BAKT1TSHR | |
| SCHEMBL28102964 | 0.84 | LMNA (0.58) | LMNAPTPN1CDC25BAKT1TSHR | |
| SCHEMBL524084 | 0.84 | LMNA (0.58) | LMNAPTPN1CDC25BAKT1TSHR | |
| SCHEMBL26563321 | 0.83 | ALDH1A1 (0.43) | LMNAL3MBTL1 | |
| SCHEMBL15084444 | 0.82 | LMNA (0.56) | LMNAPTPN1CDC25BAKT1TSHR | |
| SCHEMBL22579610 | 0.82 | LMNA (0.56) | LMNAPTPN1CDC25BAKT1TSHR | |
| SCHEMBL22579751 | 0.82 | LMNA (0.56) | LMNAPTPN1CDC25BAKT1TSHR | |
| SCHEMBL22569893 | 0.82 | LMNA (0.56) | LMNAPTPN1CDC25BAKT1TSHR | |
| SCHEMBL22569916 | 0.82 | LMNA (0.56) | LMNAPTPN1CDC25BAKT1TSHR | |
| SCHEMBL20404071 | 0.82 | LMNA (0.56) | LMNAPTPN1CDC25BAKT1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12509466-B2 | Methods and compounds for treating paramyxoviridae virus infections | GILEAD SCIENCES, INC. (US) | 2025-12-30 | — | — | US | disclosed |
| EP-4591935-A2 | METHODS FOR THE PREPARATION OF RIBOSIDES | Gilead Sciences, Inc. (US) | 2025-07-30 | — | — | EP | disclosed |
| CN-113549120-B | Method for preparing ribonucleoside | 吉利德科学公司 | 2025-04-29 | — | — | CN | disclosed |
| CN-108348526-B | Methods of treating arenaviridae and coronaviridae viral infections | 吉利德科学公司 | 2025-04-25 | — | — | CN | disclosed |
| EP-4036099-B1 | METHODS FOR THE PREPARATION OF RIBOSIDES | GILEAD SCIENCES INC (US) | 2025-03-19 | — | — | EP | disclosed |
| CN-118812607-A | Method for preparing ribonucleoside | 吉利德科学公司 | 2024-10-22 | — | — | CN | disclosed |
| CN-116617233-A | Methods of treating arenaviridae and coronaviridae viral infections | 吉利德科学公司 | 2023-08-22 | — | — | CN | disclosed |
| US-20230125751-A1 | METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2023-04-27 | — | — | US | disclosed |
| US-20230125751-A1 | METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2023-04-27 | — | — | US | disclosed |
| CN-115887465-A | Methods of treating arenaviridae and coronaviridae virus infections | 吉利德科学公司 | 2023-04-04 | — | — | CN | disclosed |
| EP-2595980-A1 | METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS | Gilead Sciences, Inc. (US) | 2013-05-29 | — | — | EP | disclosed |
| US-20120027752-A1 | METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| WO-2012012776-A1 | METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. (US) | 2012-01-26 | — | — | WO | disclosed |
| US-20110230654-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF 1'-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS | GILEAD SCIENCES, INC. (US) | 2011-09-22 | — | — | US | disclosed |
| US-20110230654-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF 1'-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS | GILEAD SCIENCES, INC. (US) | 2011-09-22 | — | — | US | disclosed |
| US-8012942-B2 | Carba-nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-8012942-B2 | Carba-nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| WO-2010093608-A1 | CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2010-08-19 | — | — | WO | disclosed |
| US-20100203015-A1 | CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2010-08-12 | — | — | US | disclosed |
| US-20100203015-A1 | CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100203015-A1 | CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | PNP, TYMP, MTAP | LMNA 1447/4885PTPN1 2744/4885CDC25B 1817/4885 |
| US-20120027752-A1 | METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS | PNP, RPIA, HPRT1 | LMNA 1211/4885PTPN1 1838/4885CDC25B 3868/4885 |
| US-20230125751-A1 | METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS | PNP, RPIA, HPRT1 | LMNA 1211/4885PTPN1 1838/4885CDC25B 3868/4885 |
| US-12509466-B2 | Methods and compounds for treating paramyxoviridae virus infections | MTAP, PNP, NSUN2 | LMNA 1169/4885PTPN1 1347/4885CDC25B 3932/4885 |
| US-20110230654-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF 1'-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS | PNP, TYMP, CDA | LMNA 1150/4885PTPN1 3598/4885CDC25B 791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.